Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jinlianhua lozenge
- Development stage
- Phase 2
- Lead developer
- Jilin Aodong Pharmaceutical Group
- Administration
- Oral
01
Overview
Jinlianhua lozenge is a traditional Chinese medicine (TCM) product developed by Jilin Aodong Yanbian Pharmaceutical Co., Ltd. for the treatment of acute pharyngitis and acute catarrhal tonsillitis. The formulation is based on the extract of *Trollius chinensis* Bunge (Jinlianhua), a plant traditionally used in China for its anti-inflammatory, antibacterial, and heat-clearing properties. It is specifically indicated for patients presenting with the wind-heat pattern of TCM. The drug has been evaluated in Phase II clinical trials in China, where its efficacy and safety were compared against Jinlianhua oral solution to provide a localized delivery method for soothing throat inflammation and reducing symptoms.
- Brand names
- Jinlianhua lozenge
- Other names
- Jinlianhua hanpian
Beyond the preview
Go deeper on Jinlianhua lozenge.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jinlianhua lozenge.